A 10-year-old boy with metastatic rhabdomyosarcoma had an HLA-identical sibling and received an allogeneic BMT. Recurrence was detected in the BM as the only site of treatment failure 12 months after BMT. Donor leukocyte infusion (DLI) was chosen as salvage therapy. Although sufficient cells (a total of 29.7 × 10 7 /kg) were infused, no signs of acute GVHD nor BM aplasia occurred and the patient died of disease progression 9 months after DLI. Keywords: rhabdomyosarcoma; alloBMT; DLI Metastatic rhabdomyosarcoma (RMS) is known to have a very poor prognosis. Despite intensive chemotherapy, there are few long-term disease-free survivors. Recently, some of these patients have been treated with high-dose chemoand radiotherapy followed by BMT rescue. The success of this approach has yet to be determined and few details of the post-transplant courses are available.
Metastatic rhabdomyosarcoma (RMS) is known to have a very poor prognosis. Despite intensive chemotherapy, there are few long-term disease-free survivors. Recently, some of these patients have been treated with high-dose chemoand radiotherapy followed by BMT rescue. The success of this approach has yet to be determined and few details of the post-transplant courses are available.
Donor leukocyte infusion (DLI) as salvage therapy for recurrent RMS after BMT has not been previously reported. This report describes a case with stage IV RMS, who underwent DLI after developing BM recurrence following an allogeneic BMT.
Case report
A 10-year-old boy was referred with pallor, fatigue and anemia in May 1994. On objective examination, pallor could be observed in the absence of organomegaly and lymphadenopathy. The PB film showed abnormal cells and the blood count was as follows: Hb 6.5 g/dl, Plts 40 × 10 9 /l and WBC 3.9 × 10 9 /l. The BM aspirate was hypercellular and 94% of the nucleated cells were blasts characterized by round nuclei, fine chromatin, prominant nucleoli and basophilic cytoplasm with vacuolation.
Immunophenotyping of the blasts revealed that both myeloid and lymphoid markers were negative. Cytoplasm of the blasts was strongly positive for periodic acid Schiff (PAS). The immunohistochemistry showed positivity of blasts for HHF35, desmin and myoglobin. The karyotype of the blasts was reported as 92, XXYY,add(1)(p1?), +2, add(2)(q?2)×2, −13, −13, −14, −14, −16, +4mar and 93, idem, +17. Subsequent studies including computed tomography of the nasopharynx identified a nasal tumor which was positive on Gallium scintigraphy. Biopsy of the nasopharyngeal mass established a diagnosis of RMS. However, the histological subtype of RMS was unclear due to the small specimen. Further extensive investigation failed to identify metastatic lesions other than in the BM. /day on days −3, −2. On day 0, the patient received 3.7 × 10 8 BM cells/kg of body weight. As prophylaxis against GVHD, MTX was administered (15 mg on day 1, 10 mg on days 3, 6, 11 and weekly thereafter). The post-transplant course was complicated by oral mucositis and liver dysfunction due to regimen-related toxicity.
Hematopoietic reconstitution was satisfactory and the WBC and ANC reached 1.0 and 0.5 × 10 9 /l, on day 20. Engraftment was confirmed on day 36 when chromosomal analysis of the BM showed 100% female cells (46,XX). Since no signs of acute GVHD were observed, MTX was discontinued after day 32 to induce a possible graft-versustumor effect. However, the patient developed no sign of acute or chronic GVHD. Repeated BM examination showed complete response and complete chimera by chromosomal analysis until December 1995, when tumor cells were found on routine BM aspiration (12 months after BMT). Cytogenetic study of BM cells also revealed that 13 of 20 cells analyzed were of recipient origin, having near-tetraploidy with t(2;13)(q35;q14) and other complex abnormalities, whereas the rest of the cells were donor type (46,XX).
Further extensive evaluation for recurrent disease disclosed no tumor apart from in the BM, and no primary site. The patient received reinduction chemotherapy consisting of VCR, AMD and CY (VAC) and a second complete response was obtained. Since the parents refused further chemotherapy because of the severe mucositis after VAC chemotherapy, we elected to give DLI as salvage therapy. The patient received DLI from his sister (BMT donor) once a month on two occasions: 7.7 × 10 7 PB nucleated cells (5.4 × 10 7 CD3 + T cells)/kg of the patient's body weight for the first course and 22.0 × 10 7 nucleated cells (15.4 × 10 7 CD3 + T cells)/kg of the patient's body weight for the second course were given in February and March 1996 (day 447, 474 following BMT, respectively). However, no evidence of GVHD or marrow aplasia was observed and the disease progressed to metastases in the right subclavicular lymph node and in multiple bones. In Apirl 1996, the patient received VAC chemotherapy again without effect and finally expired due to progressive disease in October 1996.
Discussion
Although it is well known that rhabdomyosarcoma may metastasize to the BM, extensive marrow involvement as the sole clinical manifestation of the disease is extremely rare.
1,2 More recently, a few cases of RMS presenting with diffuse BM involvement have been reported. [2] [3] [4] Patients presenting with BM involvement at the onset of disease were of older age, frequently exhibited an alveolar subtype, and had a poor prognosis with 5-year disease-free survivals of less than 7%.
1 Although the precise histological subtype was not clear, the presence of the characteristic translocation, t(2;13)(q35;q14), in tumor cells strongly suggested that this case was an alveolar RMS.
In view of the unique clinical presentation and extremely poor prognosis of the patient, we elected for allogeneic BMT rather than autologous BMT after intensive conditioning because of the availability of an HLA-identical sibling. We chose a drug combination of etoposide, carboplatin, pirarubicin and melphalan as conditioning, a regimen currently used as standard preparative regimen for autologous BMT for RMS in Japan. When relapse occurred in the BM, there was no evidence of tumor recurrence at the primary site which may indicate that more intensive therapy was necessary to eradicate all metastatic tumor cells in the BM.
Because of refusal of further chemotherapy by the parents, DLI was elected as salvage treatment after the second complete response induced by VAC. DLI is an established treatment for recurrence of CML after allogeneic BMT, while responses in other malignancies are inconsistent and transient. 5 To our knowledge, our patient is the first reported case of RMS treated by DLI. The graft-versus-leukemia effect associated with donor T cells in BMT is closely correlated with GVHD development; however, a graft-versus-leukemia effect is often observed among recipients of DLI even in the absence of GVHD. 6 Since no sign of acute GVHD was observed after DLI in this patient, it is difficult to conclude whether infused donor T cells were truly non-cytotoxic to RMS cells or not in our case. However, it is possible that a graft-versus-tumor effect for RMS may be absent since earlier studies have reported a poor outcome after allogeneic BMT for RMS. 7, 8 A comparative study of allogeneic and autologous BMT on neuroblastoma, another common childhood solid tumor, suggested no advantage of allogeneic over autologous transplants, 9, 10 possibly attributable to the lack of histocompatibility antigens on neuroblastoma cells. In this particular case of RMS, however, class I (but not class II) antigen was expressed on the surface of tumor cells obtained from BM when analyzed by FACS (data not shown). Therefore, there may be another reason for poor allo-effect in RMS. We may need a better approach for inducing a graftversus-tumor effect with allogeneic BMT for RMS such as stimulation of NK activity with IL-2 to eradicate residual tumor cells. The results of such a study in leukemias has already been reported by Slavin et al. 
